El-Ghamrawy: The visit of the WHO delegation reflects the Organization’s confidence in the Egyptian Drug Authority’s leading regulatory role.
El-Ghamrawy: We are keen to strengthen our strategic partnership with the WHO to support the pharmaceutical system in line with the highest international standards.
Naema Abed: We value the Authority’s efforts to enhance the efficiency of the pharmaceutical system and look forward to continued close cooperation with Egypt as a regional model in pharmaceutical regulation.
Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), received a high-level delegation from the World Health Organization (WHO).
During the meeting, Dr. El-Ghamrawy welcomed the delegation members, expressing his deep appreciation for the fruitful and ongoing cooperation between the EDA and WHO. He reaffirmed the Authority’s commitment to strengthening its long-term strategic partnership with the Organization to support and enhance the efficiency of Egypt’s pharmaceutical system at both the regional and international levels.
The Chairman reviewed the major achievements of the Egyptian Drug Authority, which made it one of the first regulatory bodies in the Middle East to obtain the WHO Maturity Level 3 (ML3) classification. He also highlighted that the EDA is steadily progressing toward achieving the WHO-Listed Authority (WLA) designation, reinforcing its position as a globally recognized regulatory authority aligned with Egypt’s Vision 2030, which aims to boost competitiveness in the health sector and achieve sustainable development.
Dr. Naema Abed, WHO Representative in Egypt, expressed her deep appreciation for the achievements of the EDA in governance, transparency, and institutional capacity building. She praised the Authority’s integrated approach, which combines technical, administrative, and digital development, and affirmed the WHO’s keenness to continue cooperating with the EDA to strengthen national capacities and support the advancement of Egypt’s pharmaceutical regulatory system at both the national and regional levels.
The meeting was attended on behalf of the Egyptian Drug Authority by:
• Dr. Tamer Elhossieny, Vice Chairman of the Egyptian Drug Authority
• Dr. Rasha Ziada, Chairman’s Assistant for Technical Development and Capability Building Affairs
• Dr. Yasin Ragaey, Assistant Chairman for Media and Investment Support and Supervisor of the Central Administration for Pharmaceutical Care
• Dr. Myriam Boulos, Head of the Central Administration of Medical Devices
• Dr. Asmaa Fouad, Head of the Central Administration of Biologicals, Innovative Products, and Clinical Studies
• Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access
• Dr. Wedyan Younis, Head of the Central Administration for Drug Control
• Dr. Mohab Fady, Head of the Central Administration for Licensing of Pharmaceutical Establishments
• Dr. Dalia Abu Hussein, Director of the General Administration for Quality
This visit reflects the World Health Organization’s confidence in the Egyptian Drug Authority’s leading regulatory role and reinforces its position as a regional reference authority that upholds the principles of transparency, contributing to patient safety and consolidating Egypt’s role as a regional and global hub for excellence in pharmaceutical regulation and oversight.